Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/WFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent unique, potent, and promising new options in the lung cancer treatment arsenal. Ongoing clinical trials evaluating ADCs, including those directed at trophoblast cell surface antigen 2 (TROP2), have demonstrated positive preliminary data in lung cancer, and additional results from other studies assessing monotherapy and rational combinatorial options are anticipated in the near future. As advances with TROP2-targeting ADCs continue, it is crucial for oncologists and other professionals involved in the care of patients with lung cancer to gain knowledge of the rationale, characteristics, efficacy, and different adverse event profiles of these novel therapies. They must also develop the necessary skills to enable rapid adoption of these therapies into their clinical practice should they receive regulatory approval. This educational activity